The US National Plan for AD (National Alzheimer's Project Act, NAPA) has the ambitious goal of preventing and effectively treating Alzheimer’s disease (AD) by 2025 through the support of innovative research focused on AD etiology, early detection, and therapeutics. The National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) is an NIA- funded Cooperative Agreement that serves as the primary resource for sample sharing for all NIA-funded Alzheimer’s disease and related dementias (ADRD) studies. NCRAD received a perfect score on its recent competitive renewal. Over the next five years, NCRAD will work closely with NIA and other national efforts in ADRD research to advance genomic and biomarker efforts aimed at identifying those at greatest risk for ADRD and to delay and prevent ADRD. With the rapid development of blood-based biomarkers, there is an urgency to have a central laboratory in the United States that can process large numbers of samples in a standardized manner and return the data to studies. To meet this goal, Indiana University is establishing a new biomarker laboratory that will produce key plasma assays for samples banked at the National Centralized Repository for Alzheimer’s Disease (NCRAD). NCRAD will limit its focus to biomarkers that are well established and can be implemented as commercial assays. Initial assays will be: P-tau, NfL, Aβ1-40 and Aβ1-42. NCRAD’s approach will ensure that standardization of processes and delivery of reliable and consistent research biomarker results can be achieved. It will also allow for longitudinal quality monitoring and consistent delivery of results over time as well as the opportunity for cross-lab comparability studies. There are several key advantages to centralizing the biomarker laboratory at NCRAD. First, since NCRAD banks samples from 45 studies, integrating the biomarker laboratory within NCRAD is a seamless process to return assay data to the contributing study. Second, studies without a biomarker focus can easily partner with NCRAD to include plasma biomarkers with minimal effort.